Guardant Health, Inc. Exchanges New Convertible Senior Notes for Existing Notes

Details

exchanged $600 million aggregate principal amount of new 1.25% Convertible Senior Notes due 2031 for the retirement of approximately $659.3 million principal amount of its existing 0% Convertible Senior Notes due 2027. The new notes are senior unsecured obligations governed by an indenture dated as of the closing date, with conversion rights and redemption terms detailed. Shares of common stock may be issued upon conversion, subject to certain conditions. This transaction is exempt from registration under Section 4(a)(2) of the Securities Act of 1933.

Items reported

Exhibits (1)

About Guardant Health Inc.

Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.